Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco’s Role to Include Chief Operating Officer Responsibilities

Rhea-AI Summary

Prestige Consumer Healthcare (NYSE: PBH) has expanded the role of Chief Financial Officer Christine Sacco to include Chief Operating Officer responsibilities, effective immediately. In this enhanced role, Ms. Sacco will oversee the Company's supply chain along with her existing CFO duties. She will continue to report to CEO Ron Lombardi. Lombardi highlighted Sacco's strategic leadership and deep understanding of the business, which have been instrumental in the company's growth over her 8-year tenure as CFO.

Ms. Sacco, a seasoned executive with over 27 years of experience in the consumer products and specialty pharma sectors, has been the CFO since 2016. Her tenure has seen significant contributions to Prestige's strategic transformation and financial success, including strong sales, earnings, and cash flow growth. This expanded role aims to enhance the execution of strategic initiatives and drive operational excellence, positioning Prestige for further organic and M&A growth.

Positive

• Christine Sacco's expanded role to include COO responsibilities aims to enhance operational excellence.
• Under Sacco's financial leadership, Prestige has achieved strong sales, earnings, and cash flow growth.
• The company is positioned with significant future capital allocation flexibility to drive shareholder value.

Negative

• None.

News Market Reaction – PBH

-3.07%

1 alert

-3.07% News Effect

On the day this news was published, PBH declined 3.07%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TARRYTOWN, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced that Chief Financial Officer Christine Sacco’s responsibilities have been expanded to include the role of Chief Operating Officer, effective immediately. In this enhanced position as COO/CFO, Ms. Sacco will oversee the Company’s supply chain, in addition to her existing responsibilities. Ms. Sacco will continue to report to Ron Lombardi, Chief Executive Officer of Prestige.

“Chris’ strategic leadership and deep understanding of our business has been instrumental in our growth and success over her 8 years as CFO,” said Ron Lombardi. “This expanded COO/CFO role positions us to further enhance execution of our strategic initiatives and drive operational excellence across the organization. Her proven track record in finance combined with her experience working closely with our supply chain operations uniquely positions her to drive further operational excellence and long-term organic and M&A growth for our Company in this expanded role.”

A seasoned executive with more than 27 years of leadership experience in the consumer products and specialty pharma space, Ms. Sacco has served as the Company’s Chief Financial Officer since 2016. During her tenure, she has made vital contributions to the Company’s strategic transformation and financial success. Under her financial leadership, the Company has achieved strong sales, earnings and cash flow growth over the past 8 years while positioning Prestige with significant future capital allocation flexibility to drive further shareholder value.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat^® and Summer’s Eve^® women's health products, BC^® and Goody's^® pain relievers, Clear Eyes^® and TheraTears^® eye care products, DenTek^® specialty oral care products, Dramamine^® motion sickness treatments, Fleet^® enemas and glycerin suppositories, Chloraseptic^® and Luden's^® sore throat treatments and drops, Compound W^® wart treatments, Little Remedies^® pediatric over-the-counter products, Boudreaux’s Butt Paste^® diaper rash ointments, Nix^® lice treatment, Debrox^® earwax remover, Gaviscon^® antacid in Canada, and Hydralyte^® rehydration products and the Fess^® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com

Source: Prestige Consumer Healthcare Inc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b8a99b5b-fd18-4d27-9a39-e14d1986df82

FAQ

What is the significance of Christine Sacco's expanded role at Prestige Consumer Healthcare?

Christine Sacco's expanded role to include COO responsibilities aims to enhance operational excellence and drive further growth through strategic initiatives.

What responsibilities will Christine Sacco have as COO/CFO of Prestige Consumer Healthcare?

As COO/CFO, Christine Sacco will oversee the company's supply chain in addition to her existing CFO duties.

How has Christine Sacco contributed to Prestige Consumer Healthcare's success?

During her tenure as CFO, Christine Sacco has driven strong sales, earnings, and cash flow growth while positioning the company for future shareholder value.

What experience does Christine Sacco bring to her new role at Prestige Consumer Healthcare?

Christine Sacco has over 27 years of leadership experience in the consumer products and specialty pharma sectors and has served as Prestige's CFO since 2016.

What is the impact of Christine Sacco's expanded role on Prestige Consumer Healthcare's strategic initiatives?

Christine Sacco's expanded role is expected to enhance the execution of strategic initiatives, driving operational excellence and long-term growth.